This deal makes sense if Aloxi sales take a 20% decline from generics. MGI will have to replace this revenue and buying SUPG is a quick answer to this problem. Remember MGI can pickup almost 100M in cash on any deal here and save 12.5M on milestones on Dacogen still outstanding. They also get in line on Dacogen milestones of 23.5M that JNJ will owe SUPG. There is also some remaining milestones on Nipent of 5.25M + 6M (after SUPG receives the 14M acceleration). Manuso had that strange language on his latest contract that gave him this small window on a buyout, he was definitely was trying to protect something there. If a buyout offer had materialized prior to Jan. 1, he would of lost 1,360,000 shares @10.00. The remaining question would be would MGI want the pipeline and CLIMB, or would they peel this off. Supg is in a position that a buyout will make sense soon to someone, specially if Dacogen keeps clearing these hurdles.